Daclizumab, a humanised monoclonal antibody to the interleukin 2 receptor (CD25), for the treatment of moderately to severely active ulcerative colitis: a randomised, double blind, placebo controlled, dose ranging trial

BACKGROUND: An uncontrolled pilot study demonstrated that daclizumab, a humanised monoclonal antibody to the interleukin 2 receptor (CD25), might be effective for the treatment of active ulcerative colitis. METHODS: A randomised, double blind, placebo controlled trial was conducted to evaluate the e...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Van Assche, G, Sandborn, W J, Feagan, B G, Salzberg, B A, Silvers, D, Monroe, P S, Pandak, W M, Anderson, F H, Valentine, J F, Wild, G E, Geenen, D J, Sprague, R, Targan, S R, Rutgeerts, P, Vexler, V, Young, D, Shames, R S
Formato: Artigo
Idioma:Inglês
Publicado em: BMJ Group 2006
Assuntos:
Inflammatory Bowel Disease
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC1860086/
https://ncbi.nlm.nih.gov/pubmed/16603634
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/gut.2005.089854
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados